Rehmannioside A

CAS No. 81720-05-0

Rehmannioside A( —— )

Catalog No. M19140 CAS No. 81720-05-0

Rehmannioside A is an iridoid glucoside extracted from traditional Chinese medicine Rehmannia.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 140 In Stock
10MG 211 In Stock
25MG 356 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Rehmannioside A
  • Note
    Research use only, not for human use.
  • Brief Description
    Rehmannioside A is an iridoid glucoside extracted from traditional Chinese medicine Rehmannia.
  • Description
    Rehmannioside A is an iridoid glucoside extracted from traditional Chinese medicine Rehmannia.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    Others
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    81720-05-0
  • Formula Weight
    524.5
  • Molecular Formula
    C21H32O15
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C1=CO[C@H]([C@H]2[C@@H]1[C@@H]([C@H]1[C@@]2(O1)CO)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)O)O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Liu C, et al. Rehmanniae Radix in osteoporosis: A review of traditional Chinese medicinal uses, phytochemistry, pharmacokinetics and pharmacology. J Ethnopharmacol. 2017 Feb 23;198:351-362.
molnova catalog
related products
  • Liguiritigenin-7-O-...

    Liguiritigenin-7-O-D-apiosyl-4'-O-D-glucoside is a flavanone glycoside isolated from Glycyrrhizia inflate.

  • Dalbergin

    Dalbergin exhibits similar bone conserving effect against bone-loss as estradiol treatment, it as a therapeutic candidate against postmenopausal osteoporosis.

  • Lenalidomide

    Lenalidomide (initially known as CC-5013 and marketed as Revlimid? by Celgene) is a derivative of thalidomide introduced in 2004.